Abstract
This off label randomized placebo controlled study was designed to investigate the efficacy of duloxetine a new potent dual inhibitor of serotonin and norepinephrine reuptake (SNRI) in the treatment of patients with PE. Material and Methods Men with diagnosed PE (n=25) with an intravaginal ejaculation latency time (IELT) less then one minute were enrolled and randomized in to two groups for duloxetine 30mg (DLX; n=16) or placebo (PL; n=9), administered once-daily, for the period up to 6 weeks. IELT has been considered before, after the second week and at the end of the treatment course. Erectile function was evaluated by means of SHIM questionnaire before and after the treatment period. Results Both groups were comparable by age (35±10 vs. 40±12), pretreatment IELT (DLX group 0,8±0,3 min; PL group 0,9±0,2 min), and SHIM scores (20,9± 1,6 vs. 20,1± 2,5). After 2 weeks and 6 weeks of drug administration in DLX group a significant improvement in IELT up to 10 fold (p Conclusion An SNR inhibitor duloxetine appears as highly effective treatment option in patients with PE in comparison to placebo, without erectile function disturbance, and can be recommended for larger controlled studies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
